NASDAQ: AMPH
Amphastar Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Market Cap
$829.39M
52w High
$31.26
52w Low
$16.65
P/E
11.03
Volume
1.26M
Outstanding Shares
44.09M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 25.77% over the last year. Revenue declined 1.06% over the trailing twelve months. Operating margin moved from 26.74% to 16.2%. Free cash flow declined 10.01% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/FCF, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at 16.2%. Revenue declined 1.06% — this read reverses if that trend stabilizes. Free cash flow fell 10.01% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
3
Buy
9
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 6, 2026
Q3 FY26 · EPS est $0.64 · Revenue est $180.34M
View